The components of the drug-eluting stents (DES) are: (1) delivery system, (2) platform, (3) polymer coating and (4) the drug. The drug aims to limit neointimal proliferation. The drug reservoir technology includes polymer technology (coating), reservoir technology and nonpolymeric drug release. Most of the currently available DES uses drugs that are analogous to the Limus family and include sirolimus, zotarolimus, everolimus, biolimus A9, novolimus and myolimus. In this chapter various DES such as Sirolimus-eluting Stents, Everolimus-eluting Stents, Zotarolimus-eluting Stent and Novolimus-eluting Stent with Durable Polymer, biodegradable polymers (Myolimus-eluting Stent with Biodegradable Polymer), polymer-free DES (Yukon®: Sirolimus-eluting Stents, BioFreedom™: Biolimus A9-eluting Stents, etc), platinum-chromium DES (PROMUS Element™, novel stent coatings) are discussed in detail.